Use of inhaled corticosteroids and healthcare costs in mild persistent asthma

Journal of Asthma

Volumn 44, Issue 6, 2007, Pages 479-483

  Colice, Gene ^a   Wu, Eric Q ^b   Birnbaum, Howard ^b   Daher, Maham ^b   Maryna, B Marynchenko ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

Economic analysis; Inhaled corticosteroids; Mild persistent asthma

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; STEROID;

ADOLESCENT; ADULT; ANALYTIC METHOD; ARTICLE; BILLING AND CLAIMS; CHILD; DATA BASE; DRUG MEGADOSE; ECONOMIC ASPECT; EMERGENCY WARD; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MILD PERSISTENT ASTHMA; PRACTICE GUIDELINE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AMBULATORY CARE; ASTHMA; CHILD; CHILD, PRESCHOOL; DATABASES; EMERGENCY MEDICAL SERVICES; FEMALE; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; INFANT; INSURANCE CLAIM REPORTING; MALE; MIDDLE AGED; UNITED STATES;

EID: 34547142557     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900701424124     Document Type: Article

References (28)

1. Irani AM. The challenge of mild persistent asthma. Ann Allergy Asthma Immunol 2005; 94:517-527.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. National Heart, Lung and Blood Institute, National Institutes of Health 2002; Publication 02-3659; Updated 2004 from the original document.
3. National Asthma Education and Prevention Program. Expert panel report 2: Guidelines for the diagnosis and management of asthma. National, Heart, Lung and Blood Institute, National Institutes of Health July 1997; Publication 97-4051.
4. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma National, Heart, Lung and Blood Institute. National Institutes of Health. J Allergy Clin Immunol 2002; 110:141-219.
5. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1392-1397.
6. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma. Lancet 2003; 361:1071-1076.
7. Sin DD, Man SFP. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med 2002; 162:1591-1595.
8. Suissa S, Ernst P. Inhaled corticosteroids: Impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001; 107:937-944.
9. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332-336.
10. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fagan JK, Fish JE, Ford JG, Kraft M, Lemanske RF, Leone FT, Martin RJ, Mauger EA, Pesola GR, Peters SP, Rollings NJ, Szefler SJ, Wechsler ME, Israel E; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352:1519-1528.
11. Colice G, Wu EQ, Bimbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and work loss costs associated with persistent asthma patients in a privately insured population. J Occup Environ Med 2006; 48:794-802.
12. Friedman HS, Yawn BP. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids. Curr Med Res Opin 2007; 23:427-434.
13. National Committee for Quality Assurance. Use of appropriate medications for people with asthma. HEDIS 2005, Vol 2. Technical Specifications. Washington, DC.
14. Leidy NK, Paramore LC, Watrous M, Doyle J, Zeiger RS. Development of an algorithm for estimating asthma severity from an administrative cost database. Value Health 1999; 2:394.
15. Little R, Rubin D. Statistical Analysis with Missing Data. New York, NY: John Wiley & Sons; 1987, 62-67.
16. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. J Allergy Clin Immunol 2001; 107:3-8.
17. Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, Shiboski S, Yelin EH. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111:1203-1204.
18. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity. Eur Respir J 2002; 19:61-67.
19. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12:1322-1326.
20. O'Byrne P, Cuddy L, Taylor DW, Birch S, Morris J, Syrotuik J. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can Respir J 1996; 3:169-175.
21. Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, Pauwels RA, Weiss KB. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003; 112:1229-1236.
22. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy; patient compliance, devices and inhalation technique. Chest 2000; 117:542-550.
23. Wolfenden LL, Diette GB, Krishnan JA, Skinner EA, Steinwachs DM, Wu AW. Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Intern Med 2003; 163:231-236.
24. Schatz M, Zelger RS, Vollmer WM, Mosen D, Apter AJ, Stibolt TB, Leong A, Johnson MS, Mendoza G, Cook EF. Validation of a β-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006; 117:995-1000.
25. Fuhlbrigge AL, Carey VJ, Finkelstein JA, Lozano P, Inui TS, Weiss ST, Weiss KB. Validity of the HEDIS criteria to identify children with persistent asthma and sustained high utilization. Am J Manag Care 2005; 11:325-330.
26. Mosen DM, Macy E, Schatz M, Mendoza G, Stibolt TB, McGaw J, Goldstein J, Bellows J. How well do the HEDIS asthma inclusion criteria identify persistent asthma. Am J Manag Care 2005; 11:650-654.
27. Cabana MD, Slish KK, Nan B, Clark NM. Limits of the HEDIS criteria in determining asthma severity for children. Pediatrics 2004; 114:1049-1055.
28. Berger WE, Legorreta AP, Blaiss MS, Schneider EC, Luskin AT, Stempel DA, Suissa S, Goodman DC, Stoloff SW, Chapman JA, Sullivan SD, Vollmer B, Weiss KB. The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes. Ann Allergy Asthma Immunol 2004; 93:538-545.